0001209191-19-056713.txt : 20191115 0001209191-19-056713.hdr.sgml : 20191115 20191115160719 ACCESSION NUMBER: 0001209191-19-056713 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20191113 FILED AS OF DATE: 20191115 DATE AS OF CHANGE: 20191115 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Tatsis Ourania CENTRAL INDEX KEY: 0001789815 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19319 FILM NUMBER: 191224567 MAIL ADDRESS: STREET 1: C/O VERTEX PHARMACEUTICALS, INC. STREET 2: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA CENTRAL INDEX KEY: 0000875320 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043039129 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 6173416393 MAIL ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-11-13 0 0000875320 VERTEX PHARMACEUTICALS INC / MA VRTX 0001789815 Tatsis Ourania C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON MA 02210 0 1 0 0 SVP, CRO Common Stock 2019-11-13 4 M 0 2853 155.57 A 10105 D Common Stock 2019-11-13 4 S 0 2853 205.59 D 7252 D Stock Option (Right to Buy) 155.57 2019-11-13 4 M 0 2853 0.00 D 2028-02-05 Common Stock 2853 3669 D Transaction made pursuant to Ms. Tatsis' company-approved trading plan under Rule 10b5-1. Open market sales reported on this line occurred at a weighted average price of $205.59 (range $205.57 to $205.76). Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. The option vests in 16 quarterly installments from 2/6/2018. /s/ Omar White, Attorney-in-Fact 2019-11-15